ES2101849T3 - Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma. - Google Patents

Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma.

Info

Publication number
ES2101849T3
ES2101849T3 ES92912541T ES92912541T ES2101849T3 ES 2101849 T3 ES2101849 T3 ES 2101849T3 ES 92912541 T ES92912541 T ES 92912541T ES 92912541 T ES92912541 T ES 92912541T ES 2101849 T3 ES2101849 T3 ES 2101849T3
Authority
ES
Spain
Prior art keywords
hepatocitos
gamma
growth
stimulation
interfered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912541T
Other languages
English (en)
Inventor
Paula M Jardieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2101849T3 publication Critical patent/ES2101849T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION ES RELATIVA A LA INTERACCION SINERGISTICA DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (HGF) Y DE GAMMA ERON (IFN GAMMA) EN LA ESTIMULACION DEL CRECIMIENTO DE HEPATOCITO. POR CONSIGUIENTE, LA INVENCION CONCIERNE A UN METODO DE MEJORAR LA ACTIVIDAD BIOLOGICA DE HGF ADMINISTRANDO UNA CANTIDAD BIOLOGICAMENTE EFECTIVA DE HGF Y UNA CANTIDAD SINERGISTICAMENTE EFECTIVA DE IFN GAMMA A UN PACIENTE QUE LO NECESITE.
ES92912541T 1991-06-10 1992-05-19 Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma. Expired - Lifetime ES2101849T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/712,284 US5227158A (en) 1991-06-10 1991-06-10 Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon

Publications (1)

Publication Number Publication Date
ES2101849T3 true ES2101849T3 (es) 1997-07-16

Family

ID=24861484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92912541T Expired - Lifetime ES2101849T3 (es) 1991-06-10 1992-05-19 Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma.

Country Status (12)

Country Link
US (1) US5227158A (es)
EP (1) EP0606210B1 (es)
JP (1) JPH06508148A (es)
AT (1) ATE151292T1 (es)
AU (1) AU655653B2 (es)
CA (1) CA2109434A1 (es)
DE (1) DE69218956T2 (es)
DK (1) DK0606210T3 (es)
ES (1) ES2101849T3 (es)
GR (1) GR3023613T3 (es)
WO (1) WO1992022321A1 (es)
ZA (1) ZA923980B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
DE69333950T2 (de) * 1992-05-18 2006-08-17 Genentech, Inc., South San Francisco Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
DE69310525T2 (de) * 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5855918A (en) * 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
AU7254896A (en) * 1995-10-05 1997-04-28 Genentech Inc. Improved angiogenesis using hepatocyte growth factor
WO1997012628A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Methods and compositions for treating vascular stenosis
CN1055517C (zh) * 1996-03-29 2000-08-16 唐禾天 叶片转子式发动机
US6280739B1 (en) 1996-04-18 2001-08-28 Genetics Institute, Inc. Method of inhibiting angiogenesis using secreted proteins
WO1998000543A1 (en) * 1996-07-03 1998-01-08 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
CN101612402A (zh) * 2001-01-09 2009-12-30 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7700571B2 (en) * 2002-06-05 2010-04-20 Genentech, Inc. Compositions and methods for liver growth and liver protection
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
NZ547438A (en) * 2003-12-19 2010-01-29 Genentech Inc Monovalent antibody fragments useful as therapeutics
US20050244959A1 (en) * 2004-03-30 2005-11-03 Anne Corlu Methods for inducing active hepatocytes proliferation, kits using such methods and uses of said kits
ZA200701184B (en) * 2004-07-20 2008-07-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
WO2006015371A2 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
DK1838736T3 (da) 2005-01-05 2013-06-03 Biogen Idec Inc Cripto-bindende molekyler
EP1869070B1 (en) 2005-04-15 2013-11-27 Genentech, Inc. Hgf beta chain variants
US8236761B2 (en) * 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
US7910555B2 (en) * 2006-07-07 2011-03-22 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands
CA2716670A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
TR201809743T4 (tr) 2012-01-10 2018-07-23 Biogen Ma Inc Kan beyin bariyerinden terapötik moleküllerin taşınmasının arttırılması.
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
EP3954993A1 (en) 2015-02-04 2022-02-16 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
SG11201706293XA (en) 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
RU2720451C1 (ru) * 2019-05-06 2020-04-29 Анастасия Юрьевна Лаптиёва Способ стимуляции пострезекционной пролиферации гепатоцитов путем внутрипеченочного введения цианокобаламина

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
WO1988009673A1 (en) * 1987-06-02 1988-12-15 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US4973478A (en) * 1987-07-20 1990-11-27 Allelix Biopharmaceuticals, Inc. Treating inflammation with hepatocyte stimulating factor interferon β2
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
DE69218956T2 (de) 1997-07-31
DE69218956D1 (de) 1997-05-15
WO1992022321A1 (en) 1992-12-23
EP0606210B1 (en) 1997-04-09
DK0606210T3 (da) 1997-05-05
JPH06508148A (ja) 1994-09-14
ZA923980B (en) 1993-12-01
AU2144192A (en) 1993-01-12
AU655653B2 (en) 1995-01-05
GR3023613T3 (en) 1997-08-29
EP0606210A1 (en) 1994-07-20
US5227158A (en) 1993-07-13
ATE151292T1 (de) 1997-04-15
CA2109434A1 (en) 1992-12-11

Similar Documents

Publication Publication Date Title
ES2101849T3 (es) Estimulacion del crecimiento de hepatocitos con factor de crecimiento de hepatocitos o interferon gamma.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
NZ212513A (en) Synergistic composition containing an interferon and tissue necrosis factor
DE69433870D1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
DE3583849D1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
PT858343E (pt) Terapia por infusao continua de uma dose baixa de citoquina
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
ATE94763T1 (de) Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
DE3851456D1 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
IL71954A0 (en) Gamma interferon-lymphotoxin synergism
ATE229981T1 (de) Glykolisierte cytokine
IL102753A0 (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
TW217382B (es)
DE69005837D1 (de) Verwendung bestimmter gamma-Interferone zur Behandlung von Krebs des Ovars.
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
张之南 et al. TREATMENTOFCHRONICMYELOCYTICLEUKEMIA (CML) BY TRADITIONAL CHINESE MEDICINE AND WESTERN MEDICINE ALTERNATELY
KR920014480A (ko) 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도
NO911470D0 (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 606210

Country of ref document: ES